{"id":159,"date":"2020-01-10T18:08:23","date_gmt":"2020-01-10T18:08:23","guid":{"rendered":"http:\/\/eprf.org\/?page_id=159"},"modified":"2020-01-15T15:28:45","modified_gmt":"2020-01-15T15:28:45","slug":"finished-trials","status":"publish","type":"page","link":"https:\/\/eprf.net\/index.php\/finished-trials\/","title":{"rendered":"Finished Trials"},"content":{"rendered":"

\"\"\u00a0 \u00a0 1-732-302-9990<\/a>
\n<\/span>\"\"\u00a0 \u00a0 info@eprf.net<\/a><\/span><\/span><\/p>\n<\/div>

<\/div><\/div><\/div>

The Electrophysiology Research Foundation<\/u><\/span><\/strong> is a charitable organization incorporated on August 2, 1982. The Foundation is a non-profit corporation, organized and operated exclusively for charitable purposes.<\/span><\/p>\n<\/div>

<\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div>

\"\"\u00a0 \u00a0 1-732-302-9990<\/a>
\n<\/span>\"\"\u00a0 \u00a0 info@eprf.net<\/a><\/span><\/span><\/p>\n<\/div><\/div><\/div>

<\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div>

FINISHED TRIALS<\/strong><\/span><\/h2>\n<\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>

Finished Trials<\/span><\/strong><\/h2>\n<\/div>
<\/div><\/div><\/div>

Principal Investigator<\/em>, Efficacy and Safety of Oral Cienzoline in sustained ventricular tachycardia>, Hoffman LaRoche, 1982<\/p>\n

P<\/em>rincipal Investigator<\/em>, Comparative efficacy and safety of roal cibenzoline and quinidine in ventricular arrhythmias, Hoffman LaRoche, 1983<\/p>\n

P<\/em>rincipal Investigator<\/em>, Efficacy and safety of intravenous tocainide in ventricular arrhythmias afer acute myocardial infarction, 1983-84<\/p>\n

Principal Investigator<\/em>, Efficacy of intravenous tocainide and lidocaine in ventricular arrhythmias, Merch Sharpe and Dohme, 1983-84<\/p>\n

Principal Investigator<\/em>, Efficacy of Intravenous and Oral nadolol in supraventricular tachycardia, Squibb Inc, 1983-84<\/p>\n

Principal Investigator<\/em>, Intravenous mexiletine in supraventricular tacycardia, Boehringer Ingelheim, 1983-84<\/p>\n

Principal Investigator<\/em>, Efficacy and safety of a double blind comparison of LYB5837 and Quinidine oin ventricular arrhythmias, Eli-Lilly, 1984<\/p>\n

Co-Principal investigator<\/em>, Electrophysiologic studies in diseased human ventricle in patients with sustained ventricular tachycardia, American Heart Association, New Jersey, 1983-84<\/p>\n

Principal investigator<\/em>, Long term efficacy of oral indecainide in ventricular tachycardia, Eli-Lilly, 1984<\/p>\n

Prinicipal Investigator<\/em>, Efficacy of oral propafenone in ventricular arrhythmias, Knoll Pharmaceuticals, 1984<\/p>\n

Efficacy of Cordias Omni Orthocor I in Refractory Tachycardias, Cordis Corp, 1981<\/p>\n

Principal Investigator<\/em>, Efficacy of Cordis Omni Orthocor II in Refractory Tachyarrhythmias, Cordis, 1985<\/p>\n

Principal Investigator<\/em>, Effiacy of Intracavitary Cardioversion using Medtronic 5350 external cardioverter-defibrillator, Medtronic Inc.,1984<\/p>\n

Investigator<\/em>, Automatic Implantable Cardioverter Defibrillator, Intec, 1983<\/p>\n

Comparative efficacy of sotalol versus placebo using a randomized crossover double blind study, Bristo, Myers, 1984<\/p>\n

Principal Investigator<\/em>, Comparative efficacy of milrinone, digoxin and placebo in congestive heart failure, Mead Johnson \u2013Sterling Winthrop 1985-1987<\/p>\n

Prinicipal Investigator<\/em>, Effiacy of intravenous atenolol in supraventricular tachycardia, ICI Pharmaceuticals, 1985-86<\/p>\n

Prinicipal Investigator<\/em>, Efficacy of oral xamoterol in congestive heart failure, 1985-1987<\/p>\n

Principal Investigator<\/em>, Comparative efficacy of oral mexiletine and quinidine in sustained ventricular tachycardia, Boehringer-Ingelheim, 1986-87<\/p>\n

Principal Investigator<\/em>, Long term control of ventricular arrhythmias with oral sotalol, Bristol Myers Squibb,1985<\/p>\n

Principal investigator<\/em>, Effiacy of sequential pulse defibrillation, Medtronic Inc.,1987-89<\/p>\n

Principal Investigator<\/em>, Efficacy of intravenous and oral nadolol in sustained ventricular tachycardia, Squibb, 1986-87<\/p>\n

Principal Investigator<\/em>, Effiacacy of intravenous and oral recainam in sustained ventricular tachycardia, Wyeth Ayerst, 1987-88<\/p>\n

Co- Prinicpal Investigator<\/em>, Electrophysiologic Study Versus Electrocardiographic Monitoring, RO 1 Grant, NHLBI 1987-1992<\/p>\n

Prinicipal Investigator<\/em>, Efficacy of intravenous diltiazem in supraventricular tachycardia, Marion Labs,1988-1990<\/p>\n

Principal investigator<\/em>, Comparative efficacy of oral recainam and encainide in sustained ventricular tachycardia, Wyetgh Ayerst, 1988<\/p>\n

Prinicipal Investigator<\/em>, Telectronics Meta Pulse Generator, 1988<\/p>\n

Principal investigator<\/em>, Efficacy of oral propafenone in supraventricular tachycardia, Knoll Pharmaceuticals, 1988<\/p>\n

Principal Investigator<\/em>, Effficacy of oral diprafenone in ventricular tachycardia, Berlex Labs, 1988<\/p>\n

Principal investigator<\/em>, Ventricular Defibrillation with simultaneous transvenous shocks using monophasic and biphasic shocks with the Medtronic 5350 external cardioverter-defibrillator, Medtronic Inc., 1990-91<\/p>\n

Principal investigator<\/em>, Medtronic Ventricular Defibrillation study on simultaneous transvenous defibrillation using an optimal thoracic patch lead location, Medtronic Inc.,1990-1992<\/p>\n

Co-Principal investigator<\/em>, Multicenter Automatic Implantable Cardioverter Defibrillator Trial 1, University of Rochester and Guidant Corp., 1990-1995<\/p>\n

Co-Principal Investigator<\/em>, PCD Study, Medtronic Inc., 1990-1993<\/p>\n

Co-Principal Investigator<\/em>, Intermedics Res-Q implantable cardioverter-defibrillator, Intermedics, 1995<\/p>\n

Planning and Steering Committee member and Co-Prinicipal Investigator<\/em>, Antiarrhythmics versus Implantable Defibrillator Trial, National Institutes of Health, 1994-1998<\/p>\n

Atrial Defibrillation using the Medtronic 5350 external cardioverter-defibrillator, Medtronic Inc. 1995-97<\/p>\n

Prinicipal Investigator<\/em>, Dual Site Atrial Pacing for Prevention of Atrial Fibrillation, Pilot and Main trials, Medtronic Inc., 1994-2000<\/p>\n

Principal Investigator<\/em>, Medtronic Jewel AF clinical trial in atrial fibrillation, Medtronic Inc., 1997-2000<\/p>\n

Planning and Steering Committee member and Co-Prinicipal Investigator<\/em>, AFFIRM Trial, National Institutes of Health, 1997-2002<\/p>\n

Co-Principal Investigator<\/em>, Multicenter Automatic Implantable Defibrillator Trial II, University of Rochester and Guidant Corp.,1998-2002<\/p>\n

Co-Prinicipal Investigator<\/em>, Triggers of Ventricular Arrhythmias (TOVA) Study, NHLBI, 2000-2002<\/p>\n

Principal Investigator<\/em>, Linear Radiofrequency ablation of the Right Atrium in Paroxysmal Atrial Fibrillation, Cardima Inc., 2000-2002<\/p>\n

Principal Investigator<\/em>, Multicenter Alternans Before Cardioverter Defibrillator (ABCD) Clinical Trial, 2002<\/p>\n

Principal Investigator<\/em>, Natural History of AF study, Medtronic Inc., 2000 – 2003<\/p>\n

Principal Investigator<\/em>, Biotronik Home Monitoring Trial, 2002 – 2005<\/p>\n

Prinicipal Investigator<\/em>, Procter & Gamble SHIELD study, 2001 – 2003.<\/p>\n

Principal Investigator<\/em>, Biotronik Option Study 2004 \u2013 2007<\/p>\n

Principal Investigator<\/em>, Long-Term Azimilide Study 2003 \u2013 2005<\/p>\n

National Heart Lung and Blood Institute, NIH: TOPCAT trial –\u00a0Steering committee member and co-investigator<\/em>, 2005- present<\/p>\n

The TOPCAT study is a multi-centered, international, randomized, double blind placebo-controlled study of the aldosterone antagonist spironolactone.\u00a0 The study is focused to evaluate 4500 adults with heart failure and left ventricular ejection fraction of at least 45%.\u00a0 These patients are recruited from over 150 clinical study centers.\u00a0 The trial is sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).
\nLink:\u00a0http:\/\/www.topcatstudy.com\/<\/a><\/p>\n

Study Chair<\/em>, Intracardiac Echocardiography Guided Cardioversion Helps Interventional Procedures\u00a0 (ICE-CHIP)\u00a0 study 2005 \u2013 present<\/p>\n

The ICE-CHIP study is a sequential Phase I and Phase II pilot study comparing the cardiac imaging capabilities of intracardiac echocardiography (ICE) with with transesophageal echocardiography (TEE) followed by a randomized comparison of ICE guided cardioversion with a conventional cardioversion strategy in patients with atrial fibrillation.\u00a0 The composite incidence rate of major cardiac and bleeding complications (stroke, TIA, peripheral embolism, major hemorrhagic event) will be compared between the two treatment groups over the duration of the study.<\/p>\n

Study Chair<\/em>, Hybrid Therapy In Prevention of Atrial Fibrillation (HIPPAF) study, 2006 \u2013 present<\/p>\n

Study Chair<\/em>, Intracardiac Echocardiography Guided Cardiac Resynchronization Therapy in Heart Failure\u00a0 (ICE CRT-HF)\u00a0 study 2006 \u2013 present<\/p>\n

Investigator<\/em>, \u00a0 Mulitcenter Aryx Study on New Class 3 Antiarrhythmic Agent in Paced Patients with Atrial Atrial Fibrillation 2006 \u2013 present<\/p>\n

The purpose of the Aryx study is to determine the safety and efficacy of an investigational antiarrhythmic drug.\u00a0 This drug will be used in the treatment of atrial fibrillation in patients with a double chamber pacemaker.<\/p>\n

Link:\u00a0http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00389792?order=2<\/a><\/p>\n

DR. SAKSENA\u2019S ABSTRACTS & PRESENTATIONS<\/p>\n

Manchanda SC, Guha SK, Tandon R, Saksena S, Talwar I:<\/u>\u00a0 Electrical field plethysmography.\u00a0 Studies in cardiac disease.\u00a0 Presented, 2nd All India Seminar on Bio-Control Systems, Madras, India, 1972.<\/p>\n

Roy SB, Manchanda SC, Saksena S:<\/u>\u00a0 Circulatory and ventilatory effects of high altitudes on the performance of Indian soldiers.\u00a0 Presented, Indian Council of Medical Research, 1974.<\/p>\n

Manchanda SC, Sharma R, Saksena S, Roy SB:<\/u>\u00a0 Cardiac performance during maximal exercise at high altitude.\u00a0 Presented, Annual Meeting of Association of Physicians of India and the Cardiological Society of India, 1976.<\/p>\n

Manchanda SC, Saksena S, Roy SB, Guha SK:<\/u>\u00a0 Transthoracic electrical impedance: A simple bedside technique to monitor pulmonary edema.\u00a0 Presented, Intl Symp on Biomedical Engineering, New Delhi, India, 1978.<\/p>\n

1980
\n<\/strong>
\nSaksena S, Manchanda SC, Roy SB:<\/u>\u00a0 Reduced physical work capacity at high altitude: The role of left ventricular dysfunction.\u00a0 Clin Res 1980;28:208A.<\/p>\n

Saksena S, Manchanda SC, Roy SB:\u00a0\u00a0<\/u>Cardiac performance at high altitude during maximal exercise.\u00a0 Proc VIIIth Eur Congr Cardiol 1980;1:211.<\/p>\n

Saksena S, Garcia E, Fain J, Mallon SM, Myerburg RJ:<\/u>\u00a0 Computerized regional wall motion analysis: Limitations of the right anterior oblique projection. Clin Res 1980;28:208A.<\/p>\n

Juma Z, Saksena S, Raphan C, Sung RJ:<\/u>\u00a0 Electrophysiological effects of N-acetyl procainamide (NAPA) in man.\u00a0 Clin Res 1980;28:184A.<\/p>\n

Sung RJ, Saksena S, Juma Z, Waxman HL:<\/u>\u00a0 Ventriculo-atrial conduction patterns in patients with dual atrioventricular nodal pathways.\u00a0 Proc VIIIth Eur Congr Cardiol 1980;1:213.<\/p>\n

Juma Z, Saksnea S, Raphan C, Sung RJ:<\/u>\u00a0 Pharmaco-electrophysiology of N-acetyl procainamide.\u00a0 Presented Annual Meeting, Canad Cardiovasc Soc, Winnipeg, 1980.<\/p>\n

Juma Z, Saksena S, Levy S, Wolff GS, Sung RJ:<\/u>\u00a0 Electrophysiologic characteristics of nodo-ventricular bypass tract conduction in patients with dual atrioventricular nodal pathways.\u00a0 Circulation 1980;62:III-47.<\/p>\n

1981
\n<\/strong>
\nBernstein AD, Parsonnet V, Saksena S, Shilling E:<\/u>\u00a0 Threshold curve approximations for pacemaker output programming.\u00a0 PACE 1981;4:A-33.<\/p>\n

Parken P, Saksena S, Bernstein AD, Rodgers TK, Parsonnet V:<\/u>\u00a0 Computer stimulation of complex cardiac arrhythmias: Preliminary evaluation of an electrophysiologic model.\u00a0 PACE 1981;4:A-242.<\/p>\n

Parsonnet V, Shilling E, Saksena S, Malec R:<\/u>\u00a0 How dangerous is sudden cessation of pacemaker function?\u00a0 PACE 1981;4:A-242.<\/p>\n

Bernstein AD, Parsonnet V, Saksena S, Shilling E:<\/u>\u00a0 Threshold curve approximations for pacemaker output programming.\u00a0 Presented, IInd Eur Symp on Cardiac Pacing, 1981.<\/p>\n

Saksena S, Bernstein AD, Rathyen W, Smith JP, Parsonnet V:<\/u>\u00a0 Epicardial and endocardial mapping in recurrent ventricular tachycardia: Preliminary evaluation of a microcomputer system.\u00a0 Chest 1981;80:385.<\/p>\n

Saksena S, Parken P, Bernstein AD, Rodgers TK, Parsonnet V:<\/u>\u00a0 A computer model for macro-reentrant cardiac dysrhythmias.\u00a0 Clin Res 1981;29:659A.<\/p>\n

Saksena S, Bernstein AD, Rathyen W, Smith JP, Parsonnet V:<\/u>\u00a0 A microcomputer system for cardiac mapping in recurrent ventricular tachycardia.\u00a0 Clin Res 1981;29:659A.<\/p>\n

19.\u00a0Saksena S:<\/u>\u00a0 Limitations of current techniques for induction of ventricular tachycardia.\u00a0 Clin Res 1981;29:659A.<\/p>\n

Bernstein AD, Saksena S, Rathyen W, Parsonnet V:<\/u>\u00a0 Microcomputer system for serial cardiac potential mapping.\u00a0 Presented, Intl Conf Non-Invasive Techniques, Bombay, India, 1981.<\/p>\n

Saksena S:<\/u>\u00a0 Late electrophysiologic effects of oral amiodarone hydrochloride in refractory ventricular tachycardia.\u00a0 Presented, Intl Conf Non-Invasive Techniques, Bombay, India, 1981.<\/p>\n

1982
\n<\/strong>
\nSaksena S, Rothbart S, Kaufmann WE, Rathyen W:<\/u>\u00a0 Chronic electrophysiologic, systemic and pharmacologic effects of amiodarone in recurrent ventricular tachycardia.\u00a0 Am J Cardiol 1982;49:1044.<\/p>\n

Saksena S, Rothbart S, Cappello G. Pantopoulos D:<\/u>\u00a0 Mechanisms and clinical implications of variant QRS patterns during right ventricular endocardial pacing.\u00a0 Clin Res 1982;30:678A.<\/p>\n

Saksena S, Rothbart S, Cappello G:<\/u>\u00a0 An analysis of prospective predictors of amiodarone efficacy in refractory ventricular tachycardia.\u00a0 Clin Res 1982;30:682A.<\/p>\n

Saksena S, Rothbart S, Cappello G, Pantopoulos D, Bernstein A, Somani P:<\/u>\u00a0 An appraisal of chronic lorcainide therapy in refractory ventricular tachycardia.\u00a0 Clin Res 1982;30:683A.<\/p>\n

1983
\n<\/strong>
\nSaksena S:<\/u>\u00a0 Functional sinoatrial node disorders with dual atrioventricular nodal pathways.\u00a0 Clin Res 1983;31:215A.<\/p>\n

Ferguson D, Saksena S, Greenberg E, Craelius W:<\/u>\u00a0 Management of recurrent ventricular tachycardia:\u00a0 Economic impact of therapeutic alternatives.\u00a0 Clin Res 1983;31:296A.<\/p>\n

Saksena S, Rothbart S, Craelius W, Cappello G, Pantopoulos D:<\/u>\u00a0 Comparative pharmaco-electrophysiology of intravenous and oral amiodarone in refractory ventricular tachycardia.\u00a0 Clin Res 1983;31:254A.<\/p>\n

Saksena S, Rothbart S, Craelius W, Cappello G, Pantopoulos D:<\/u>\u00a0 Electrophysiologic and pharmacologic effects of continuous intravenous admiodarone infusion in refractory ventricular tachycarida.\u00a0 Clin Res 1983;31:250A.<\/p>\n

Saksena S, Pantopoulos D, Rothbart S, Craelius W, Werres R:<\/u>\u00a0 Mechanisms of left ventricular dysfunction during ventricular tachycardia and ventricular pacing in man.\u00a0 Clin Res 1983;31:216A.<\/p>\n

Saksena S, Craelius W, Hussain SM, Parsonnet V:<\/u>\u00a0 Intraoperative spectral analysis of ventricular electrograms during sinus rhythm and ventricular tachycardia.\u00a0 Clin Res 1983;31:216A.<\/p>\n

Jacobs J, Saksena S, Rothbart S, Pantopoulos D:<\/u>\u00a0 Value of programmed cardiac stimulation with acute drug testing in refractory supraventricular tachycardia.\u00a0 Clin Res 1983;31:194A.<\/p>\n

Ferguson D, Saksena S, Greenberg E, Craelius W:<\/u>\u00a0 Clinical and economic impact of electrophysiologic evaluation for ventricular tachycardia: A three-year study.\u00a0 PACE 1983;6:312.<\/p>\n

Saksena S, Rothbart S, Cappello G, Pantopoulos D, Craelius W:<\/u>\u00a0 Ventricular tachycardia induction during electrophysiologic studies: Role of the stimulation mode.\u00a0 PACE 1983;6:318.<\/p>\n

Craelius W, Saksena S, Hussain SM, Pantopoulos D, Parsonnet V:<\/u>\u00a0 Intraoperative spectral analysis of ventricular potentials during sinus rhythm and ventricular tachycardia.\u00a0 PACE 1983;6:321.<\/p>\n

Saksena S, Rothbart S, Cappello G, Craelius W:<\/u>\u00a0 Electrophysiologic and pharmacologic effects of continuous intravenous amiodarone infusion in refractory ventricular tachycardia.\u00a0 Clin Res 1983;31:692A.<\/p>\n

Saksena S, Pantopoulos D, Rothbart S, Craelius W, Werres R:<\/u>\u00a0 Mechanisms of left ventricular function during ventricular pacing and ventricular tachycardia in man.\u00a0 PACE 1983;6:A-105.<\/p>\n

Saksena S, Craelius W, Hussain SM, Pantopoulos D, Parsonnet V:<\/u>\u00a0 Intraoperative spectral analysis of ventricular electrograms during sinus rhythm and ventricular tachycardia.\u00a0 PACE 1983;6:A-116.<\/p>\n

Saksena S:<\/u>\u00a0 Functional sinoatrial node disorders.\u00a0 An association with dual atrioventricular nodal pathways.\u00a0 PACE 1983;6:A-116.<\/p>\n

Jacobs J, Saksena S, Rothbart S:<\/u>\u00a0 Role of electrophysiologic studies with acute drug testing in refractory supraventricular tachycardia.\u00a0 PACE 1983;6:A-126.<\/p>\n

Ferguson D, Saksena S, Greenberg E, Craelius W:<\/u>\u00a0 Management of ventricular tachycardia: Economic impact of therapeutic alternatives – A three-year study.\u00a0 PACE 1983;6:A-139.<\/p>\n

Rothbart S, Saksena S, Craelius W, Cappello G, Pantopoulos D:<\/u>\u00a0 Comparative pharmaco-electrophysiology ofintravenous and oral amiodarone in refractory ventricular tachycardia.\u00a0 PACE 1983;6:A-314.<\/p>\n

Rothbart S, Saksena S, Hussain SM, Parsonnet V, Craelius W:<\/u>\u00a0 ECG effects of endocardial resection: A comparative study.\u00a0 Clin Res 1983;31:215A.<\/p>\n

Saksena S, Craelius W, Liptak K:<\/u>\u00a0 Pharmaco-electrophysiology of mexiletine in refractory ventricular tachycardia.\u00a0 Clin Res 1983;31:672A.<\/p>\n

Saksena S, Rothbart ST, Liptak K:<\/u>\u00a0 Optimising amiodarone therapy for refractory ventricular tachycardia.\u00a0 Clin Res 1983;31:672A.<\/p>\n

Craelius W, Levine RS, Saksena S, Hussain SM, Pantopoulos D, Rothbart S:<\/u>\u00a0 A practical approach to epicardial mapping during open heart surgery.\u00a0 Trans Biomed Eng BME 1983;30:493.<\/p>\n

1984
\n<\/strong>
\nSaksena S, Ciccone J, Rothbart ST, Liptak K, Craelius W:<\/u>\u00a0 Efficacy of transvenous cardioversion in ventricular tachycardia: A prospective randomized study.\u00a0 J Am Coll Cardiol 1984;3:554.<\/p>\n

Craelius W, Saksena S, Pantopoulos D, Hussain SM, Parsonnet V, Gielchinsky I:<\/u>\u00a0 Frequency analysis of cardiac potentials: A new technique for ventricular tachycardia detection.\u00a0 J Am Coll Cardiol 1984;3:581.<\/p>\n

Craelius W, Saksena S, Pantopoulos D, Rothbart ST:<\/u>\u00a0 Frequency characteristics of antegrade and retrograde human atrial potentials.\u00a0 J Am Coll 1984;Cardiol 3:582.<\/p>\n

Saksena S, Parsonnet V, Pantopoulos D, Rothbart ST, Hussain SM, Gielchinsky I:<\/u>\u00a0 Experience with an implantable antitachycardia system.\u00a0 Presented, 6th Intl Sem on Cardiac Arrhythmias, Trento, Italy, 1984.<\/p>\n

Saksena S, Parsonnet V:<\/u>\u00a0 Antitachycardia pacemaker systems.\u00a0 Symp on Physiol Pacing, Madrid, Spain, 1984.<\/p>\n

Saksena S, Rothbart ST, Shah Y, Tranotti K:<\/u>\u00a0 Chronic effects of oral cibenzoline in refractory ventricular tachycardia.\u00a0 Presented, Ann Meeting, Amer Soc Clin Pharmacol and Therapeutics, 1984.<\/p>\n

Craelius W, Saksena S, Pantopoulos D, Rothbart ST:<\/u>\u00a0 Frequency spectra of retrograde atrial potentials: Relationship to ventricular conduction patterns.\u00a0 Clin Res 1984;32:157A.<\/p>\n

Rothbart ST, Saksena S:<\/u>\u00a0 Exercise related ventricular tachycardia: The role of electrophysiologic studies.\u00a0 Clin Res 1984;32:201A.<\/p>\n

Shah Y, Saksena S, Ciccone J, Rothbart ST, Tranotti K, Pantopoulos D:<\/u>\u00a0 Factors influencing the efficacy of transvenous cardioversion for sustained ventricular tachycardia.\u00a0 Clin Res 1984;32:205A.<\/p>\n

Shah Y, Saksena S, Ciccone J, Rothbart ST, Tranotti K:<\/u>\u00a0 Determinants of success and failure during transvenous cardioversion for ventricular tachycardia.\u00a0 PACE 1984;7:464.<\/p>\n

Saksena S, Pantopoulos D, Parsonnet V, Rothbart ST, Hussain SM, Gielchinsky I, Lombardo S:<\/u>\u00a0 Clinical evaluation of an implantable antitachycardia system.\u00a0 PACE 1984;7:476.<\/p>\n

Saksena S, Rothbart ST, Shah Y, Tranotti K:<\/u>\u00a0 Chronic effects of oral cibenzoline in refractory ventricular tachycardia.\u00a0 PACE 1984;7:476.<\/p>\n

Saksena S, Nanda NC, Rosenbloom M, Ciccone J, Craelius W, Rothbart ST:<\/u>\u00a0 Hemodynamic and echocardiographic studies of left ventricular function during ventricular tachycardia.\u00a0 PACE 1984;7:477.<\/p>\n

Saksena S, Craelius W, Pantopoulos D, Rothbart ST:<\/u>\u00a0 Influence of ventriculo-atrial conduction patterns on frequency spectra of retrograde atrial potentials.\u00a0 PACE 1984;7:477.<\/p>\n

Saksena S, Ciccone J, Rothbart ST, Liptak K, Craelius W:<\/u>\u00a0 A prospective randomized study of transvenous cardioversion in ventricular tachycardia. Eur Ht J 1984;5:Suppl I-198.<\/p>\n

Saksena S, Rothbart ST, Shah Y, Liptak K:<\/u>\u00a0 Electropharmacologic effects of chronic oral cibenzoline in refractory ventricular tachycardia.\u00a0 Eur Ht J 1984;5:Suppl I-228.<\/p>\n

Craelius W, Saksena S, Chen V, Rothbart S, Pantopoulos D:<\/u>\u00a0 Spectral analysis of human arterial blood pressure.\u00a0 Clin Res 1984;32:157A.<\/p>\n

Saksena S, Nanda NC, Rosenbloom M, Ciccone JM, Craelius W, Rothbart ST:<\/u>\u00a0 Left ventricular function in ventricular tachycardia: Hemodynamic and echocardiographic studies. \u00a0Clin Res 1984;32:203A.<\/p>\n

Saksena S, Pantopoulos D, Parsonnet V, Rothbart ST, Hussain SM, Gielchinsky I, Lombardo S:<\/u>\u00a0 The value of an implantable antitachycardia system in patients with recurrent sustained tachycardias.\u00a0 Clin Res 1984;32:203A.<\/p>\n

Saksena S, Rothbart ST, Shah Y, Tranotti K:<\/u>\u00a0 Efficacy and electropharmacology of oral cibenzoline in ventricular tachycardia.\u00a0 Clin Res 1984;32:203A.<\/p>\n

Saksena S, Shah Y, Boccodamo R, Rothbart ST:<\/u>\u00a0 Comparative efficacy of transvenous cardioversion and pacing in ventricular tachycardia: A prospective randomized crossover study.\u00a0 Circulation 1984;70:II-406.<\/p>\n

Wasty N, Saksena S, Barr MJ:<\/u>\u00a0 Comparative efficacy of oral cibenzoline and quinidine on ventricular arrhythmias: a prospective randomized crossover study.\u00a0 Circulation 1984;70:II-406.<\/p>\n

1985
\n<\/strong>
\nSaksena S, Ciccone J, Chandran P, Rothbart ST, Pantopoulos D, Lee B:<\/u>\u00a0 Laser ablation of normal and diseased human ventricle.\u00a0 J Am Coll Cardiol 1985;5:473.<\/p>\n

Saksena S, Goldberg W, Rothbart ST:<\/u>\u00a0 The electropharmacology and long-term clinical efficacy of mexiletine in refractory ventricular tachycardia.\u00a0 J Am Coll Cardiol 1985;5:482.<\/p>\n

Calvo R, Saksena S, Barr MJ:<\/u>\u00a0 Electrophysiologic effects, efficacy and safety of oral moricizine hydrochloride in sustained ventricular tachycardia.\u00a0 J Clin Pharmacol Therapeu 1985;253:10.<\/p>\n

Saksena S, Ciccone J, Chandran P, Pantopoulos D:<\/u>\u00a0 Argon laser ablation of human ventricle: Dose-response studies in normal and diseased tissues.\u00a0 Presented, Intl Symp on Fulguration and Laser in Cardiac Arrhythmias, Paris, France, April 1985.<\/p>\n

Ciccone J, Saksena S, Pantopoulos D:<\/u>\u00a0 Continuous and pulsed argon laser ablation of human diseased ventricle – a comparative study.\u00a0 Clin Res 1985;33:175A.<\/p>\n

Lavery D, Saksena S, Rothbart ST, Barr MJ:<\/u>\u00a0 Long-term clinical efficacy of electrophysiologically-guided amiodarone therapy for refractory sustained ventricular tachycardia.\u00a0 Clin Res 1985;33:302A.<\/p>\n

Rothbart S, Ciccone J, Saksena S:<\/u>\u00a0 Transvenous cardioversion – Mechanisms of ventricular tachycardia termination and acceleration.\u00a0 PACE 1985;8:302.<\/p>\n

Saksena S, Shah Y, Boccadomo R, Calvo R, Kowey P, Barr MJ, Olukotun O:<\/u>\u00a0 Intravenous nadolol for refractory supraventricular tachycardia: Mechanisms, electropharmacology, efficacy and safety.\u00a0 PACE 1985;8:305.<\/p>\n

Saksena S, Wasty N, Hussain SM, Gielchinsky I, Parsonnet V:<\/u>\u00a0 Efficacy of subendocardial resection is related to the site of origin of ventricular tachycardia.\u00a0 PACE 1985;8:306.<\/p>\n

Ciccone J, Saksena S, Pantopoulos D:<\/u>\u00a0 Comparative efficacy of continuous and pulsed argon laser ablation of diseased human ventricle.\u00a0 PACE 1985;8:318.<\/p>\n

Rothbart ST, Ciccone J, Saksena S:<\/u>\u00a0 Mechanism of ventricular tachycardia termination and acceleration during transvenous cardioversion.\u00a0 PACE 1985;8(II):A-39.<\/p>\n

80.\u00a0Saksena S, Wasty N, Hussain SM, Gielchinsky I, Parsonnet V:<\/u>\u00a0 Site of origin of ventricular tachycardia influences efficacy of subendocardial resection.\u00a0 PACE 1985;8(II):A-88.<\/p>\n

Calvo R, Saksena S, Barr MJ:<\/u>\u00a0 Clinical efficacy, electrophysiologic effects and safety of oral ethmozine in sustained ventricular tachycardia.\u00a0 PACE 1985;8(II):A-97.<\/p>\n

Calvo R, Saksena S, Rothbart ST, Pantopoulos D:<\/u>\u00a0 Efficacy and safety of a combined pacing and transvenous cardioversion algorithm in ventricular tachycardia: A prospective randomized study.\u00a0 Circulation 1985;72:III-383.<\/p>\n

1986
\n<\/strong>
\nRothbart ST, Saksena S, Pantopoulos D, Calvo R:<\/u>\u00a0 Efficacy and safety of transvenous cardioversion and rapid ventricular tachycardia using two energy waveforms: A prospective randomized study.\u00a0 J Am Coll Cardiol 1986;7:73A.<\/p>\n

Gordon S, Lavery D, Calvo K, Saksena S:<\/u>\u00a0 Doppler overestimation of systolic aortic valve gradient in patients with aortic regurgitation.\u00a0 J Am Coll Cardiol 1986;7:73A.<\/p>\n

Saksena S, Rothbart ST, Calvo R, Pantopulos D, Hussain SM:<\/u>\u00a0 Mechanism of efficacy of transvenous cardioversion of ventricular tachyarrhythmias as determined by cardiac mapping in man.\u00a0 J Am Coll Cardiol 1986;7:73A.<\/p>\n

Lavery D, Saksena S, Gordon S, Rothbart ST, Barr MJ:<\/u>\u00a0 Long-term efficacy of amiodarone therapy in refractory sustained ventricular tachycardia: The role of electrophysiologic studies and ambulatory monitoring.\u00a0 J Am Coll Cardiol 1986;7:91A.<\/p>\n

Saksena S, Calvo RA, Rothbart ST, Pantopoulos D:<\/u>\u00a0 High power rapid pulsed argon laser ablation of diseased human ventricle.\u00a0 PACE 1986;9:299.<\/p>\n

Switzer D, Saksena S, Nanda N, Calvo R, Rothbart ST, Calvo K:<\/u>\u00a0 Color and pulsed Doppler flow mapping of mitral blood flow during sustained ventricular tachycardia.\u00a0 PACE 1986;9:301.<\/p>\n

Calvo RA, Saksena S, Pantopoulos D, Rothbart ST:<\/u>\u00a0 Comparison of a single and two simultaneous transvenous shocks in rapid ventricular tachycardia.\u00a0 Clin Res 1986;34:287A.<\/p>\n

Chandran P, Saksena S, Rothbart ST, Barr MJ:\u00a0 Electrophysiologically-guided treatment of sustained ventricular tachycardia:<\/u>\u00a0Evaluation of an algorithm incorporating pharmacologic, electrical and surgical therapy.\u00a0 Clin Res 1986;34:288A.<\/p>\n

Gordon S, Lavery D, Calvo K, Saksena S:<\/u>\u00a0 Noninvasive estimation of left ventricular end diastolic pressure by Doppler ultrasound in patients with aortic regurgitation.\u00a0 Clin Res 1986;34:304A.<\/p>\n

Saksena S, Calvo RA, Gadhoke A, Pantopulos D:<\/u>\u00a0 Comparison of continuous wave and high power pulsed argon laser ablation in diseased human ventricle.\u00a0 Clin Res 1986;34:340A.<\/p>\n

Saksena S, Rothbart ST, Calvo RA, Pantopoulos D:<\/u>\u00a0 Effects of varying laser power output on laser ablation of human diseased ventricle.\u00a0 Clin Res 1986;34:341A.<\/p>\n

Saksena S, Rothbart ST:<\/u>\u00a0 Acute hemodynamic effects of low and high energy intracardiac shocks for ventricular tachycardia cardioversion and arrhythmia ablation in man.\u00a0 Clin Res 1986;34:341A.<\/p>\n

Saksena S, Calvo RA, Pantopoulos D, Gordon S, Gadhoke A:<\/u>\u00a0 Simultaneous shocks for ventricular tachycardia cardioversion: Effect of electrode position on efficacy.\u00a0 Clin Res 1986;34:341A.<\/p>\n

Saksena S, Calvo RA, Pantopoulos D, Rothbart ST, Gadhoke A:<\/u>\u00a0 Cardioversion of rapid ventricular tachycardia with two simultaneous transvenous shocks in man.\u00a0 Clin Res 1986;34:341A.<\/p>\n

Switzer D, Saksena S, Nanda N, Calvo RA, Rothbart ST, Calvo K:<\/u>\u00a0 Color and pulsed Doppler flow mapping of mitral flow during sustained ventricular tachycardia.\u00a0 Clin Res 1986;34:347A.<\/p>\n

Saksena S, Calvo RA, Pantopoulos D, Gordon S, Gadhoke A:<\/u>\u00a0 Simultaneous shocks for ventricular tachycardia cardioversion: Effect of electrode position.\u00a0 Proc X World Congr of Cardiol, 1986;p 483.<\/p>\n

Saksena S, Kesselbrenner M, Rothbart ST, Gadhoke A:<\/u>\u00a0 Hemodynamic effects of low and high energy intracardiac shocks in man.\u00a0 Proc X World Congr of Cardiol, 1986;p 185.<\/p>\n

Calvo R, Saksena S, Rothbart ST, Pantopoulos D, Gadhoke A:<\/u>\u00a0 Comparison of a single and two simultaneous transvenous shocks in rapid ventricular tachycardia.\u00a0 Proc X World Congr of Cardiol, 1986;p 185.<\/p>\n

Pantopoulos D, Calvo R, Rothbart S, Saksena S:<\/u>\u00a0 Ventricular tachycardia termination with pacing and cardioversion,\u00a0 Presented, 3rd Natl Conf on Cardiac Pacing & Electrophysiol, New Delhi, India, Feb 1986.<\/p>\n

Rothbart ST, Saksena S, Calvo RA, Pantopoulos D:<\/u>\u00a0 Improved results with antitachycardia pacemakers for refractory ventricular tachycardia.\u00a0 Circulation 1986;74:II-184.<\/p>\n

Saksena S, Hussain SM, Gielchinsky I, Gadhoke A, Pantopoulos D:<\/u>\u00a0 Successful mapping-guided argon laser ablation of ventricular tachycardia in man.\u00a0 Circulation 1986;74:II-186.<\/p>\n

Saksena S, Tarjan P, Bharati S, Boveja B, Cohen D, Joubert T:<\/u>\u00a0 A new technique for successful low energy His bundle ablation using a suction electrode catheter.\u00a0 Circulation 1986;74:II-387.<\/p>\n

Saksena S, Gadhoke, Pantopoulos D, Osypka P:<\/u>\u00a0 Radiofrequency ablation of arrhythmogenic diseased human ventricle.\u00a0 Circulation 1986;74:II-461.<\/p>\n

1987
\n<\/strong>
\nLindsay BD, Rothbart ST, Wasty N, Pantopoulos D, Saksena S:<\/u>\u00a0 Prospective evaluation of ven tricular pacing and high energy transvenous shocks using a triple electrode array for cardioversion of ventricular tachycardia.\u00a0 J Am Coll Cardiol 1987;9:141A.<\/p>\n

Wasty N, Pantopoulos D, Rothbart ST, Cohen L, Saksena S:<\/u>\u00a0 Detection of sustained ventricular tachyarrhythmias using right ventricular hemodynamic parameters: A prospective study.\u00a0 J Am Coll Cardiol 1987;9:141A.<\/p>\n

Wasty N, Saksena S, Parsonnet V, Hussain SM, Gielchinsky I, Shepherd M:<\/u>\u00a0 Long-term efficacy and complications of antitachycardia pacemakers compared with implantable defibrillators.\u00a0 J Am Coll Cardiol 1987;9:143A.<\/p>\n

Saksena S, Hussain SM, Gielchinsky I, Pantopoulos D, Wasty N, Rothbart ST, Alizadeh J:<\/u>\u00a0 Intraoperative mapping-guided argon laser ablation of malignant supraventricular and ventricular tachycardia.\u00a0 J Am Coll Cardiol 1987;9:249A.<\/p>\n

Saksena S, Rothbart ST, Gadhoke A, Hussain SM, Gielchinsky I:<\/u>\u00a0 Anatomic, hemodynamic and electrophysiologic effects of argon laser endocardial ablation for refractory ventricular tachycardia in man.\u00a0 PACE 1987;10:411.<\/p>\n

Saksena S, Furman R, Gadhoke A, Osypka P:<\/u>\u00a0 Feasibility of radiofrequency ablation of supraventricular and ventricular tachyarrhythmias.\u00a0 PACE 1987;10:414.<\/p>\n

Saksena S, Rothbart ST, Lindsay BD, Calvo RA, Pantopoulos D:<\/u>\u00a0 Is there an optimal termination algorithm for transvenous cardioversion of ventricular tachycardia?\u00a0 PACE 1987;10:416.<\/p>\n

Saksena S, Hussain SM, Gielchinsky I, Gadhoke A, Pantopoulos D:<\/u>\u00a0 Laser ablation of human atrium and accessory pathways: Experimental observations and early clinical experience.\u00a0 PACE 1987;10:427.<\/p>\n

Saksena S, Rothbart ST, Calvo RA, Pantopoulos D:<\/u>\u00a0 Comparison of single and dual current pathways for transvenous cardioversion in rapid ventricular tachycardia.\u00a0 PACE 1987;10:446.<\/p>\n

Calvo RA, Rothbart ST, Saksena S, Barr MJ, Gadhoke A:<\/u>\u00a0 Improved efficacy with combined mexiletine\/quinidine therapy in ventricular tachycardia.\u00a0 Clin Res 1987;35:265A.<\/p>\n

Saksena S, Rothbart ST, Schwarz T, Barr MJ, Herman S:<\/u>\u00a0 Combination therapy improves survival in patients with persistently inducible ventricular tachycardia on amidarone.\u00a0 Clin Res 1987;35:323A.<\/p>\n

Gielchinsky I, Hussain SM, Saksena S:<\/u>\u00a0 Clinical efficacy and safety of intraoperative mapping-guided laser endocardial ablation in patients with malignant supraventricular and ventricular tachycardia.\u00a0 PACE 1987;10(II):681.<\/p>\n

Saksena S, Rothbart ST, Lindsay BD, Calvo RA, Pantopoulos D:<\/u>\u00a0 Combined pacing and shock therapy for transvenous cardioversion of ventricular tachycardia.\u00a0 PACE 1987;10(I):607.<\/p>\n

Saksena S, Rothbart ST, Lindsay BD, Calvo RA, Pantopoulos D:<\/u>\u00a0 Selection of the optimal tachycardia termination mode: Comparison of two algorithms for transvenous cardioversion of ventricular tachycardia.\u00a0 PACE 1987;10(II):737.<\/p>\n

Saksena S, Rothbart ST, Schwarz T, Barr MJ, Herman S:<\/u>\u00a0 Outcome of combination therapy in patients with persistently inducible ventricular tachycardia on amiodarone.\u00a0 PACE 1987;10(II):737.<\/p>\n

Saksena S, Calvo RA, Pantopoulos D, Rothbart ST:<\/u>\u00a0 A prospective evaluation of single and dual current pathways for transvenous cardioversion in rapid ventricular tachycardia.\u00a0 PACE 1987;10(II):738.<\/p>\n

Saksena S:<\/u>\u00a0 Laser ablation for tachyarrhythmia control: Development and expectations.\u00a0 PACE 1987;10(II):1027.<\/p>\n

Saksena S:<\/u>\u00a0 Future developments for implantable cardioverters and defibrillators.\u00a0 PACE 1987;10(II):1041.<\/p>\n

Saksena S, Lim F Jr, Prasher S, An HL:<\/u>\u00a0 Feasibility of transcatheter argon laser ablation for ventricular tachyarrhythmias.\u00a0 Circulation 1987;76(II):IV-278.<\/p>\n

Saksena S, Parsonnet V, Pantopoulos D, Rothbart ST:<\/u>\u00a0 Transvenous cardioversion and defibrillation of ventricular tachyarrhythmias using bidirectional shocks: Acute feasibility studies and chronic device implantation.\u00a0 Circulation 1987;76(II):IV-311.<\/p>\n

Steinberg JS, Freedman RA, for the ESVEM Investigators:<\/u>\u00a0 The signal averaged ECG does not predict drug efficacy in sustained ventricular arrhythmias.\u00a0 Circulation 1987;76(II):IV-344.<\/p>\n

Rothbart ST, Saksena S, Barr MJ:<\/u>\u00a0 Chronic amiodarone therapy for refractory ventricular tachycardia: Improved patient survival and toxicity management with combination therapy – a five-year study.\u00a0 Circulation 1987;76(II):IV-367.<\/p>\n

Saksena S, Rothbart ST, Barr MJ, Herman S, Munsif AN, Wasty N, Olukotun AY:<\/u>\u00a0 Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.\u00a0 Circulation 1987;76(II):IV-511.<\/p>\n

Milrinone Multicenter Trial Group:<\/u>\u00a0 Oral milrinone and digoxin in heart failure: Results of a placebo controlled prospective trial of each agent and the combination.\u00a0 Circulation 1987;76(II):IV-256.<\/p>\n

1988
\n<\/strong>
\nAn HL, Saksena S, Lim F Jr, Prasher S, Janssen M:<\/u>\u00a0 Ventricular ablation with radiofrequency energy: Comparison of different catheter energy delivery systems.\u00a0 J Am Coll Cardiol 1988;11:17A.<\/p>\n

Saksena S, An HL, Herman S, Marcantuono D:<\/u>\u00a0 Clinical outcome of patients with intact atrioventricular conduction after atrioventricular junction ablation for refractory supraventricular tachyarrhythmias.\u00a0 J Am Coll Cardiol 1988;11:177A.<\/p>\n

Saksena S, Munsif AN, Hussain SM, Gielchinsky I:<\/u>\u00a0 Long-term clinical results of intraoperative mapping-guided argon laser ablation of malignant supraventricular and ventricular tachycardias.\u00a0 J Am Coll Cardiol 1988;11:178A.<\/p>\n

Saksena S, An HL, Pantopoulos D:<\/u>\u00a0 Rapid transvenous cardioversion of sustained ventricular tachycardia by programmable implantable cardioverters\/defibrillators.\u00a0 J Am Coll Cardiol 1988;11:209A.<\/p>\n

Saksena S, An HL, Marcantuono D, Janssen M, Osypka P:<\/u>\u00a0 Pulsed radiofrequency ablation with conventional electrode catheter: Experimental studies and early clinical observations.\u00a0 PACE 1988;11:489.<\/p>\n

An HL, Saksena S, Pantopoulos D:<\/u>\u00a0 Prospective comparison of combined transvenous catheter and cutaneous electrodes with catheter electrodes alone for ventricular tachycardia cardioversion.\u00a0 PACE 1988;11:492.<\/p>\n

Saksena S, Heselmeyer T, Batsford W, Morse DP, Porterfield JG, Gessman L, Pantopoulos D,Marcantuono D, Rosenfeld LE, McPherson CA, Elefteriades J, White M, Raman S, Serbent R:<\/u>\u00a0 Long-term clinical experience with a versatile antitachycardia pacemaker for tachycardia termination, induction and monitoring.\u00a0 A multicenter study.\u00a0 PACE 1988;11:493.<\/p>\n

Saksena S, Gielchinsky I:<\/u>\u00a0 Intraoperative selection of laser ablation site in patients with sustained ventricular tachycardia.\u00a0 PACE 1988;11:528.<\/p>\n

Saksena S:<\/u>\u00a0 Improved nonepicardial electrode systems for implantable cardioverter\/defibrillators.\u00a0 PACE 1988;11:882.<\/p>\n

Moser S, Troup P, Saksena S, Parsonnet V, Furman S, Fisher J, Thomas A:<\/u>\u00a0 Non-thoracotomy implantable defibrillator system.\u00a0 PACE 1988;11:887.<\/p>\n

Saksena S:<\/u>\u00a0 Catheter ablation of tachycardias with laser energy: Issues and answers.\u00a0 PACE 1988;11:906.<\/p>\n

Gielchinsky I, Saksena S, Kaushik R, Alizadeh J, Pantopoulos D:<\/u>\u00a0 Results of intraoperative laser ablation of malignant ventricular and supraventricular tachycardias.\u00a0 PACE 1988;11:935.<\/p>\n

Saksena S:<\/u>\u00a0 New techniques of the automatic implantable defibrillator.\u00a0 Presented, Intl Symp on Ventricular Tachyarrhythmias, Hanover, FRG, 1988.<\/p>\n

Saksena S, Tullo N, Parsonnet V, Giechinsky I, Karanam R:<\/u>\u00a0 Initial clinical experience with an implantable cardioverter-defibrillator using a nonepicardial electrode system.\u00a0 Circulation 1988;78:II-220.<\/p>\n

1989
\n<\/strong>
\nSaksena S, Gielchinsky I, Tullo NG:<\/u>\u00a0 Electrophysiologic effects of argon laser irradiation during intraoperative atrioventricular node or accessory pathway ablation in man.\u00a0 J Am Coll Cardiol 1989;13:169A.<\/p>\n

An H, Saksena S:<\/u>\u00a0 Comparative effects of radiofrequency and laser ablation in normal and diseased ventricular myocardium.\u00a0 J Am Coll Cardiol 1989;13:175A.<\/p>\n

Freedman RA, Fuller MS, Steinberg JD, for the ESVEM Investigators:<\/u>\u00a0 Effect of antiarrhythmic drugs on frequency-domain parameters of signal-averaged ECG.\u00a0 J Am Coll Cardiol 1989;13:191A.<\/p>\n

Saksena S, Tullo NG, Krol RB, Parsonnet V, Gielchinsky I, Karanam R:<\/u>\u00a0 Clinical evaluation of an implantable cardioverter\/defibrillator with nonepicardial leads in patients with refractory ventricular tachyarrhythmias.\u00a0 J Am Coll Cardiol 1989;13:215A.<\/p>\n

An H, Saksena S:<\/u>\u00a0 Optimal catheter electrode dimensions for non-thoracotomy
\ncardioversion\/defibrillation lead systems.\u00a0 J Am Coll Cardiol 1989;13:216A.<\/p>\n

Krol RB, Saksena S, Tullo NG, An H:\u00a0<\/u>\u00a0Electrode configuration for optimal defibrillation with nonepicardial lead systems for cardioverter\/defibrillators.\u00a0 PACE 1989;12(I):646.<\/p>\n

Saksena S, Scott S, Accorti P, Boveja B, Callaghan F, Abels D:<\/u>\u00a0 Improved pacing and internal defibrillation using a porous electrode catheter with biphasic unidirectional and bidirectional shocks.\u00a0 PACE 1989;12(I):663.<\/p>\n

An H, Saksena S:<\/u>\u00a0 Optimal location of patch electrode for non-thoracotomy cardioversion\/defibrillation lead systems.\u00a0 PACE 1989;12(I):681.<\/p>\n

Saksena S, Gielchinsky I, Tullo NG, Krol RB:<\/u>\u00a0 Intraoperative map-guided argon laser ablation for refractory supraventricular and ventricular tachycardia: A three year experience.\u00a0 PACE 1989;12(I):687.<\/p>\n

Saksena S, Krol RB, Tullo NG, Mauro AM:<\/u>\u00a0 Intraoperative and postoperative evaluation of nonepicardial lead systems for implantable cardioverter\/defibrillators.\u00a0 PACE 1989;12(I):687.<\/p>\n

154.\u00a0Anastasiou-Nana MI, Anderson JL, Gilbert EM, Miller RH, Singh S, Freedman RA, Somberg JC, Saksena S, Urquilla PR:<\/u>\u00a0 Suppression of chronic ventricular arrhythmias with sotalol: Final report of a multicenter randomized double-blind, placebo-controlled trial.\u00a0 Circulation 1989;80:II-641.<\/p>\n

1990
\n<\/strong>
\nSaksena S, Castle L, Fogoros R, Alpert B, Kron J, Pacifico A, Griffin J, Ruskin J, Kehoe R, Yee R, Dorian P, Kerr C, Luceri R, Sakun V, Guardian Investigators:<\/u>\u00a0 Initial clinical experience with second generation implantable defibrillator.\u00a0 J Am Coll Cardiol 1990;15:55A.<\/p>\n

An H, Saksena S, Mehra R, Tullo N, Krol R, Smits K:<\/u>\u00a0 Effect of right ventricular cathode configuration on endocardial cardioversion and defibrillation with dual electrode systems and monophasic shocks.\u00a0\u00a0 PACE 1990;13:511.<\/p>\n

Saksena S, Makhija V, Tullo N, Krol R, Brown J, Gielchinsky I, Saxena A, Karanam R:<\/u>\u00a0 Device activation and clinical outcome of patients with implantable cardioverter\/defibrillators for ventricular tachyarrhythmias.\u00a0 PACE 1990;13:528.<\/p>\n

Krol R, Saksena S, Tullo N, Karanam R, Gielchinsky I, Saxena A, Holwitt K, Lipsius M<\/u>:\u00a0 Clinical experience with bipolar epicardial sensing for a combined implantable pacemaker-defibrillator.\u00a0 PACE 1990;13:536.<\/p>\n

Tullo N, Saksena S, Krol R, Mauro AM:<\/u>\u00a0 Sensing characteristics of endocardial lead systems for implantable defibrillators.\u00a0 PACE 1990;13:546.<\/p>\n

Saksena S, Accorti P, Scott S, Abels D, Boveja B, Callaghan F:<\/u>\u00a0 Endocardial defibrillation with biphasic shocks using porous leads.\u00a0 Clin Res 1990;38:502A.<\/p>\n

Saksena S, Castle L, Fogoros R, Alpert B, Kron J, Pacifico A, Griffin J, Ruskin J, Kehoe R, Luceri R, Yee R, Dorian P, Kerr C, Sakun V:<\/u>\u00a0 Use of programmability with the Guardian implantable defibrillator.\u00a0 Rev Eur Tec Bio 1990;12:111.<\/p>\n

162.\u00a0Puchferran R, Castle L, Saksena S, Fogoros R, Alpert B, Kron J, Pacifico A, Griffin J, Ruskin J, Kehoe R, Luceri R, Yee R, Dorian P, Kerr C:<\/u>\u00a0 Chronic electrophysiology study experience with the Guardian implantable defibrillator.\u00a0 Rev Eur Tec Bio 1990;12:111.<\/p>\n

Castle L, Saksena S, Fogoros R, Alpert B, Kron J, Pacifico A, Griffin J, Ruskin J, Kehoe R, Luceri R, Yee R, Dorian P, Kerr C, Sakun V, Guardian Investigators:<\/u>\u00a0 Initial experience with second generation implantable defibrillator.\u00a0 Rev Eur Tec Bio 1990;12:112.<\/p>\n

Saksena S, Makhija V, Tullo N, Krol R, Brown J, Gielchinsky I, Saxena A, Karanam R:<\/u>\u00a0 Device activation and clinical outcome of patients with implantable cardioverter\/defibrillators.\u00a0 Rev Eur Tec Bio 1990;12:114.<\/p>\n

Saksena S, Luceri R, Tullo N, Krol R, Braunstein S, Accorti P, Scott S, Singh S, Burkhardt E, Brewer G, Callaghan F:<\/u>\u00a0 Initial clinical experience with a second generation endocardial lead system for implantable cardioverter-defibrillators.\u00a0 Rev Eur Tec Bio 1990;12:114.<\/p>\n

166.\u00a0An H, Saksena S, Mehra R, Tullo N, Krol R, Smits K:<\/u>\u00a0 Effect of right ventricular cathode configuration on endocardial cardioversion and defibrillation.\u00a0 Rev Eur Tec Bio 1990;12:114.<\/p>\n

Saksena S, Accorti P, Scott S, Abels D, Boveja B, Callaghan F:<\/u>\u00a0 Endocardial defibrillation with biphasic shocks using porous leads: Effect of electrode materials and configuration.\u00a0 Rev Eur Tec Bio 1990;12:121.<\/p>\n

Saksena S, An H, Mehra R, Tullo N, Krol R, Smits K:<\/u>\u00a0 Energy delivery during endocardial cardioversion and defibrillation of ventricular tachyarrhythmias in man.\u00a0 Rev Eur Tec Bio 1990;12:126.<\/p>\n

Saksena S, An H, Krol R, Tullo N:<\/u>\u00a0 Modification of atrioventricular conduction after direct current catheter ablation.\u00a0 Rev Eur Tec Bio 1990;12:147.<\/p>\n

An H, Saksena S:<\/u>\u00a0 A comparison of radiofrequency and laser catheter ablation.\u00a0 Rev Eur Tec Bio 1990;12:148.<\/p>\n

An H, Saksena S, Tullo N, Krol R:<\/u>\u00a0 Arcing during radiofrequency ablation of supraventricular tachyarrhythmias.\u00a0 Rev Eur Tec Bio 1990;12:148.<\/p>\n

Saksena S, Luceri R, Tullo NG, Krol RB, Brownstein S, Singh S, Accorti P, Brewer G, Scott S, Burkhardt E, Callaghan F:<\/u>\u00a0 Clinical efficacy and safety of a braided endocardial pacing and defibrillator lead system for ventricular tachycardia and ventricular fibrillation using monophasic and biphasic shocks.\u00a0 Circulation \u00a01990;82:III-166.<\/p>\n

173.\u00a0Saksena S, Krol RB, Tullo NG, Gielchinsky I, Saxena A, Burkhardt E:<\/u>\u00a0 Endocardial and epicardial diastolic electrical activation patterns during sustained ventricular tachycardia.\u00a0 Circulation 1990;82:III- 474.<\/p>\n

Greenberg GM, Dustman TJ, Fuller MS, Lux RL, Anderson KP, and the ESVEM Investigators:<\/u>\u00a0 Initiation of spontaneous sustained monomorphic ventricular tachycardia.\u00a0 Circulation 1990;82:III-580.<\/p>\n

1991
\n<\/strong>
\n175.\u00a0Tullo NG, Saksena S, Krol RB, Singh S, Burkhardt E, Hibbard D:<\/u>\u00a0 Sensing characteristics of first- and second-generation endocardial (non-thoracotomy) lead systems for implantable cardioverter-defibrillators.\u00a0 J Am Coll Cardiol 1991;17:54A.<\/p>\n

An H, Saksena S, Tullo NG, Krol RB, Burkhardt E, Mehra R, DeGroot P:<\/u>\u00a0 Comparison of epicardial and endocardial lead systems for an implantable third-generation hybrid cardioverter-defibrillator.\u00a0 J Am Coll Cardiol 1991;17:55A.<\/p>\n

Krol RB, Saksena S, Tullo NG, Singh S, Saxena A, Karanam R, Gielchinsky I, Burkhardt E, Gordon M, Hibbard D:<\/u>\u00a0 Optimal pacing and sensing lead systems for implantable hybrid pacemaker-cardioverter-defibrillators.\u00a0 J Am Coll Cardiol 1991;17:55A.<\/p>\n

Krol RB, Saksena S, Tullo NG, Saxena A, Suri RS, Gordon M, Burkhardt E, Hibbard D, Neglia J:<\/u>\u00a0 Clinical efficacy of antitachycardia pacing in patients with ventricular tachyarrhythmias with implanted third-generation cardioverter-defibrillators.\u00a0 J Am Coll Cardiol 1991;17:86A.<\/p>\n

Saksena S, Krol RB, Tullo NG, Gielchinsky I:<\/u>\u00a0 Long-term outcome of laser ablation alone or in combination with endocardial resection in ventricular tachycardia.\u00a0 J Am Coll Cardiol 1991;17:225A.<\/p>\n

Saksena S, Castle L, Fogoros R, Alpert B, Kron J, Pacifico A, Griffin J, Ruskin J, Kehoe R, Yee R, Dorian P, Kerr C, Luceri R, Poczobutt-Johanas M, Poliseno M, for Guardian Investigators Group & Telectronics Pacing Systems:<\/u>\u00a0 Multicenter clinical investigation of a second generation programmable pacemaker-cardioverter-defibrillator.\u00a0 J Am Coll Cardiol 1991;17:344A.<\/p>\n

Saksena S, Krol RB, Tullo NG, Makhija V, Kunecz D, Gordon M:<\/u>\u00a0 Patterns of device activation for multi-programmable and non-programmable implantable cardioverter-defibrillators.\u00a0 J Am Coll Cardiol 1991;17:344A.<\/p>\n

Ellenbogen K, Welch W, Luceri R, Jackman W, Singer I, Dorian P, Saksena S, Brachman J, Renker M, and Phase I:<\/u>\u00a0 Clinical evaluation of the Guardian ATP 4210 implantable pacemaker\/defibrillator:\u00a0 Worldwide experience.\u00a0 PACE 1991;14(II):623.<\/p>\n

Hamill S, Stanton M, Packer D, and the PCD Investigator Group:<\/u>\u00a0 The effect of therapy type (autodecremental, burst, cardioversion) on subsequent ventricular tachycardia cycle length in patients with an implantable antitachycardia pacing-cardioversion-defibrillation device.\u00a0 PACE 1991;14(II):623.<\/p>\n

Wilber DJ, Poczobutt-Johanas, and the Guardian Clinical Investigators:<\/u>\u00a0 Time-dependent sensing alterations in implantable defibrillators: Lessons from the Telectronics Guardian 4202\/4203.\u00a0 PACE 1991;14(II):624.<\/p>\n

Saksena S, An H, Krol RB, Burkhardt E:<\/u>\u00a0 Simultaneous biphasic shocks enhance efficacy of endocardial cardioversion-defibrillation in man.\u00a0 PACE 1991;14(II):624.<\/p>\n

Saksena S, Ward D, Krol RB, Camm AJ:<\/u>\u00a0 Efficacy of braided endocardial defibrillation leads: Acute testing and chronic implant.\u00a0 PACE 1991;14(II):719.<\/p>\n

Markham J, Mehta D, Marchese T, Pacetti P, Saksena S, Haffajee C:<\/u>\u00a0 Predictors of success and initial human experience with nonthoracotomy implantation of a permanent pacer-cardioverter-defibrillator device.\u00a0 PACE 1991;14(II):722.<\/p>\n

The ESVEM Investigators:<\/u>\u00a0 Determinants of a drug efficacy prediction in the ESVEM trial: Differences between electrophysiological study (EPS) and Holter monitoring (HM).\u00a0 Circulation 1991;84:II-348.<\/p>\n

Mason JW and The ESVEM Investigators:<\/u>\u00a0 Unsustained VT as a predictor of spontaneous sustained VT in the ESVEM study.\u00a0 Circulation 1991;84:II-348.<\/p>\n

Ellenbogen K, Luceri R, Dorian P, Brachman J, Uther J, Beckman K, Singer I, Zipes D, Saksena S, Estes M, Franklin J, and Phase I Clinical Investigators:<\/u>\u00a0 Clinical evaluation of implantable cardioverter defibrillator (CD) function: Importance of data logging to assess device efficacy.\u00a0 Circulation 1991;84:II-426.<\/p>\n

Saksena S, Luceri R, Krol RB, Accorti P, Brewer G, Scott S, Burkhardt E, Callaghan F:<\/u>\u00a0 Endocardial cardioversion-defibrillation using braided endocardial leads and simultaneous biphasic shocks.\u00a0 Circulation 1991;84:II-610.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-159","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages\/159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/comments?post=159"}],"version-history":[{"count":6,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages\/159\/revisions"}],"predecessor-version":[{"id":303,"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/pages\/159\/revisions\/303"}],"wp:attachment":[{"href":"https:\/\/eprf.net\/index.php\/wp-json\/wp\/v2\/media?parent=159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}